Two New gMG Approvals, One Increasingly Competitive Market

By Sarah Soucy, Franchise Head, Neuroscience & Ophthalmology, Spherix Global Insights

In the span of less than a week, the FDA approved two new targeted therapies: AstraZeneca/Alexion’s Klygefa (gefurulimab) and Regeneron’s Livsayis (cemdisiran). Both target the complement C5 pathway but bring differentiated approaches to the gMG treatment landscape.

For a market that has already experienced significant innovation over the past five years, these approvals represent a new step as the first dual-binding nanobody (Klygefa) and small interfering RNA (Livsayis) to be approved for gMG in the US. While expanding treatment options is welcome news for patients and physicians, the increasingly crowded landscape raises interesting questions about how these therapies will be positioned and adopted.

Two Approvals, Two Different Approaches

Klygefa enters the market offering once-weekly subcutaneous self-administration via an autoinjector. Building on AstraZeneca/Alexion’s established complement inhibitor franchise, Klygefa introduces another option for patients seeking greater treatment flexibility.

Livsayis brings a different innovation as the first approved siRNA therapy for gMG. Its quarterly subcutaneous administration offers a meaningful reduction in treatment frequency over existing C5 inhibitors and FcRn blockers.

A Growing Market Where Differentiation Matters

With multiple targeted therapies competing for a, physicians face increasingly complex treatment decisions. Efficacy, safety, mechanism of action, patient preference on administration, treatment burden, and access all influence prescribing.

Will quarterly administration give Livsayis a competitive advantage? How much will physicians value Klygefa’s self-administration flexibility? Will these therapies primarily attract patients switching from existing advanced treatments, or expand the population receiving a targeted therapy?

And how will payers respond as competition intensifies?

Ultimately, clinical differentiation is only part of the equation. Understanding how physicians translate these considerations into treatment decisions will be critical to determining commercial success.

Tracking the Market Beyond the Approvals

Spherix Global Insights will continue tracking the physician perceptions, patient-level treatment decisions, and competitive dynamics shaping the next chapter of gMG care through complementary research offerings:

  • RealTime Dynamix™ tracks physician perceptions, treatment preferences, unmet needs, and competitive positioning.
  • Patient Chart Dynamix™ examines patient-level treatment patterns, sequencing, switching, and factors driving therapeutic decisions.
  • Launch Dynamix™ monitors physician awareness, early adoption, prescribing behaviors, and barriers to uptake following new product introductions.
  • Patient Voice Dynamix™ captures patients’ treatment experiences, unmet needs, and preferences, providing insight into how convenience, disease burden, and quality of life influence treatment decisions.
  • Patient Services Dynamix™ offers comparative intelligence and brand-level best practices to strengthen patient support programs and improve execution across access pathways.

Together, these insights help connect what physicians think, how patients are treated, and how new therapies perform in an increasingly competitive market. Our preliminary publication plan is available here and will be updated with the latest advancements in gMG.

Interested in understanding how the gMG market is evolving? Connect with Spherix Global Insights to learn more about our ongoing research and upcoming launch coverage.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sign up for alerts, market insights and exclusive content in your inbox.

Related Articles

Market Access   •   Media Coverage
Market Access   •   Media Coverage
Corporate   •   Media Coverage